Discover how lipid nanoparticles (LNPs) are powering a new era of personalized nanomedicine. Nanoparticle delivery systems are making bedside RNA therapies a reality.
A paradigm shift: from mass production to personalized RNA therapies
Imagine a future where life-saving RNA therapies are not manufactured months in advance in distant facilities, but instead prepared on-demand, tailored to an individual patient’s genetic profile, and formulated right at the hospital pharmacy or by a nearby Contract Manufacturing Organization (CMO).
This future is closer than we think.
A recent publication in Frontiers in Science introduces NANOSPRESSO, a European initiative that aims to make personalized, bedside production of nucleic acid nanomedicines into clinical practice. By combining microfluidic technology with lipid nanoparticles (LNPs), NANOSPRESSO proposes a compact, modular system for patient-specific RNA-LNP therapies, all built on the same concept that revolutionized coffee: the capsule.
However, for this model to work, it requires nanoparticle platforms that are safe, efficient, easy to use, and adaptable to many therapeutic scenarios. That is where DIVERSA comes in.
Why personalization matters in nanomedicine
- Nucleic acid therapeutics, such as mRNA, siRNA or CRISPR, are redefining how we treat diseases. They allow us to:
- Replace or silence faulty genes
- Produce missing proteins
- Program immune responses in cancer.
Nevertheless, the therapeutic payload is only one piece of the puzzle. These molecules need protection, delivery to the right cells, and efficient uptake, functions provided by LNPs. In addition, when the RNA drug changes from patient to patient, the LNP formulation process must also change.
This is the essence of personalized nanomedicine: not just choosing the right target but building the right delivery vehicle for that specific therapeutic, at that specific moment.
DIVERSA: innovative lipid nanoparticles for personalized therapies
At DIVERSA, we are developing fully biodegradable, regulatory-safe LNPs that are:
- Innovative: our unique composition increases stability, safety, and efficacy.
- Flexible: compatible with mRNA, siRNA, CRISPR, and more.
- Scalable: effective in both high-throughput settings and small-scale, bedside use.
Our platforms are aligned with the NANOSPRESSO model, enabling clinicians and pharmacists to quickly mix therapeutic RNA with our nanoparticles and obtain functional RNA-formulations, ready for clinical use.
In short, DIVERSA provides a delivery engine that powers the personalized medicine machine.
Bringing the future closer: the path ahead
DIVERSA shares the same goal as NANOSPRESSO: to democratize access to advanced genetic therapies, especially for rare diseases and oncology.
Thanks to recent advances in microfluidics, regulatory flexibility, and platform nanomedicine, the pieces are already falling into place. Personalized nanomedicine is no longer science fiction.
With delivery platforms like those from DIVERSA, we are entering an era where bespoke RNA therapies can be designed, produced, and administered on demand. This is not just about convenience. It’s about treating patients more effectively, equally, and on time.
At DIVERSA, we are proud to be enabling this shift, because personalized medicine starts with smart delivery.
Visit www.diversatechnologies.com or send an email to info@diversatechnologies.com to explore our solutions.
References
Internal References
- How nanotechnology is shaping the future of personalized medicine
- Beyond the liver: Unlocking extrahepatic delivery with lipid nanoparticles
- Overcoming regulatory hurdles in clinical translation of nanomedicine
- Nanomedicine in 2024: Key Advances and Future Directions
External References
- Estapé Senti, M., Ceccaldi, A., Luciani, M., Saber, N., Schurmann, P. J., Geerlings, M. W., … & Cullis, P. (2025). NANOSPRESSO: toward personalized, locally produced nucleic acid nanomedicines. Frontiers in Science, 3. 10.3389/fsci.2025.1458636.
